6576 Stock Overview
Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Foresee Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$94.10 |
| 52 Week High | NT$107.50 |
| 52 Week Low | NT$75.30 |
| Beta | 1.14 |
| 1 Month Change | -2.89% |
| 3 Month Change | 0.53% |
| 1 Year Change | 4.67% |
| 3 Year Change | -6.37% |
| 5 Year Change | 17.48% |
| Change since IPO | -14.84% |
Recent News & Updates
Shareholder Returns
| 6576 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -3.0% | -2.2% | -1.6% |
| 1Y | 4.7% | 7.2% | 25.9% |
Return vs Industry: 6576 underperformed the TW Pharmaceuticals industry which returned 7.2% over the past year.
Return vs Market: 6576 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 6576 volatility | |
|---|---|
| 6576 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6576 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6576's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Ben Chien | www.foreseepharma.com |
Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases.
Foresee Pharmaceuticals Co., Ltd. Fundamentals Summary
| 6576 fundamental statistics | |
|---|---|
| Market cap | NT$12.78b |
| Earnings (TTM) | -NT$1.04b |
| Revenue (TTM) | NT$195.04m |
65.5x
P/S Ratio-12.3x
P/E RatioIs 6576 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6576 income statement (TTM) | |
|---|---|
| Revenue | NT$195.04m |
| Cost of Revenue | NT$81.07m |
| Gross Profit | NT$113.97m |
| Other Expenses | NT$1.15b |
| Earnings | -NT$1.04b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.63 |
| Gross Margin | 58.44% |
| Net Profit Margin | -531.33% |
| Debt/Equity Ratio | 16.1% |
How did 6576 perform over the long term?
See historical performance and comparison